Bluefin Capital Management’s Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares FLAC Stock Holding History

Bluefin Capital Management’s Portfolio FLAC Stock Details FLAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-71,143	Closed	-$694K	–	1093
2021 Q4	$694K	Buy	71,143 +3,500	+5%	+$34.3K	0.05%	278
2021 Q3	$660K	Buy	+67,643	New	+$661K	0.07%	218

Other funds holding FLAC

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

DCM

DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

Governors Lane New York $1.2B AUM 26.21% 1-Year Est. Return

Bluefin Capital Management's FLAC Position: Q1 2022 in Review

Bluefin Capital Management sold out of Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares (FLAC) in Q1 2022, closing a stake of 71,143 shares — an estimated $694K sold.

Bluefin Capital Management first reported a position in FLAC in Q3 2021 and held it in 2 quarters. The position peaked at $694K in Q4 2021. 49 funds tracked by Wall St. Rank hold FLAC as of Q1 2022.

Bluefin Capital Management reported no remaining Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position as of Q1 2022 after selling out during the quarter.
Bluefin Capital Management sold 71,143 Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares shares in Q1 2022, an estimated $694K.
Bluefin Capital Management first reported a position in Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares in Q3 2021 and held it in 2 quarters.
Bluefin Capital Management's Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position peaked at $694K in Q4 2021.
49 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.